Chronic Oral p38α:MK2 Dual Signal Modulators

About GEn1E Lifesciences

GEn1E Lifesciences is a private, clinical-stage biotech accelerating first-in-class therapies for inflammatory and rare diseases. Its lead asset, GEn-1124, is a dual p38α:MK2 signal modulator in Phase 2 for ARDS, developed in collaboration with BARDA. The company's core differentiator is its GRID™ AI platform, which enables rapid identification of novel allosteric binding pockets and has propelled its lead program from discovery to Phase 2 in just 2.5 years using seed capital.

Therapeutic Areas